{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:47:16Z","timestamp":1780343236494,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2020R1F1A1070341"],"award-info":[{"award-number":["2020R1F1A1070341"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI21C0940"],"award-info":[{"award-number":["HI21C0940"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.labinv.2024.102126","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T11:40:52Z","timestamp":1724326852000},"page":"102126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Significance of the Immune Microenvironment in Endometrial Cancer"],"prefix":"10.1016","volume":"104","author":[{"given":"Miseon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonkyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongseok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-0917","authenticated-orcid":false,"given":"Jun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7447","key":"10.1016\/j.labinv.2024.102126_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.labinv.2024.102126_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A\u00a0clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.labinv.2024.102126_bib3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.labinv.2024.102126_bib4","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.labinv.2024.102126_bib5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.labinv.2024.102126_bib6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.6004\/jnccn.2018.0067","article-title":"NCCN guidelines insights: colorectal cancer screening, Version 1.2018","volume":"16","author":"Provenzale","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.labinv.2024.102126_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.labinv.2024.102126_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.labinv.2024.102126_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: from prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.labinv.2024.102126_bib10","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.labinv.2024.102126_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.5081","article-title":"Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response","volume":"245","author":"Temko","year":"2018","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.labinv.2024.102126_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2015.04.027","article-title":"Polymerase \u03b5 (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients","volume":"138","author":"Bellone","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.labinv.2024.102126_bib13","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.labinv.2024.102126_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.labinv.2024.102126_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2009.03.022","article-title":"Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer","volume":"114","author":"de Jong","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.labinv.2024.102126_bib16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1097\/IGC.0b013e31822c271f","article-title":"Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer","volume":"21","author":"Yamagami","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.labinv.2024.102126_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.labinv.2024.102126_bib18","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.3390\/cancers15194899","article-title":"Enhanced risk stratification in early-stage endometrial cancer: integrating POLE through droplet digital PCR and L1CAM","volume":"15","author":"Joe","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2024.102126_bib19","series-title":"Female Genital Tumours, WHO Classification of Tumours","year":"2020"},{"issue":"2","key":"10.1016\/j.labinv.2024.102126_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41379-021-00882-y","article-title":"Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists","volume":"35","author":"Mills","year":"2022","journal-title":"Mod Pathol"},{"issue":"15","key":"10.1016\/j.labinv.2024.102126_bib21","doi-asserted-by":"crossref","first-page":"e14589","DOI":"10.1200\/JCO.2017.35.15_suppl.e14589","article-title":"Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx","volume":"35","author":"Kulangara","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.labinv.2024.102126_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2024.01.032","article-title":"The emerging and challenging role of PD-L1 in patients with gynecological cancers: an updating review with clinico-pathological considerations","volume":"184","author":"Santoro","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.labinv.2024.102126_bib23","article-title":"Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer","volume":"33","author":"Kim","year":"2022","journal-title":"J\u00a0Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.labinv.2024.102126_bib24","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1186\/s12885-018-5127-6","article-title":"Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study","volume":"18","author":"Jang","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.labinv.2024.102126_bib25","article-title":"Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types","volume":"12","author":"Shen","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"issue":"13","key":"10.1016\/j.labinv.2024.102126_bib26","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1158\/1078-0432.CCR-0732-3","article-title":"Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma","volume":"10","author":"Kondratiev","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.labinv.2024.102126_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000493010","article-title":"Zone formation of lymphocyte infiltration at invasive front as a biomarker of prognosis in endometrial carcinomas","volume":"96","author":"Miyamoto","year":"2019","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.labinv.2024.102126_bib28","first-page":"5555","article-title":"Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma","volume":"34","author":"\u010cerm\u00e1kov\u00e1","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.labinv.2024.102126_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.labinv.2024.102126_bib30","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A\u00a0radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.labinv.2024.102126_bib31","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.labinv.2024.102126_bib32","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1158\/1078-0432.CCR-16-1031","article-title":"Regression of chemotherapy-resistant polymerase \u03b5 (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab","volume":"22","author":"Santin","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.labinv.2024.102126_bib33","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.labinv.2024.102126_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"10.1016\/j.labinv.2024.102126_bib35","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.labinv.2024.102126_bib36","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.3390\/cancers15164032","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitor as single-agent immunotherapy in endometrial cancer: a systematic review and meta-analysis","volume":"15","author":"Mamat Yusof","year":"2023","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.labinv.2024.102126_bib37","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.3390\/cancers14163911","article-title":"PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis","volume":"14","author":"Yusof","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.labinv.2024.102126_bib38","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1007\/s12325-019-01057-7","article-title":"Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non\u2013small-cell lung cancer (NSCLC)","volume":"36","author":"Incorvaia","year":"2019","journal-title":"Adv Ther"},{"issue":"17","key":"10.1016\/j.labinv.2024.102126_bib39","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.labinv.2024.102126_bib40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.labinv.2024.102126_bib41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.labinv.2024.102126_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","article-title":"Tumor area positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring","volume":"18","author":"Liu","year":"2023","journal-title":"Diagn Pathol"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002368372401804X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002368372401804X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:51:04Z","timestamp":1756687864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002368372401804X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S002368372401804X"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2024.102126","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Significance of the Immune Microenvironment in Endometrial Cancer","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2024.102126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102126"}}